SAN DIEGO--(BUSINESS WIRE)--Scale Biosciences (Scale BioTM), a leader in innovative and scalable single cell analysis solutions, and Revvity’s (NYSE: RVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research.

圣地亚哥--（商业新闻短讯）--创新和可扩展单细胞分析解决方案的领导者Scale Biosciences（Scale BioTM）和世界一流生物试剂和工具的领先供应商Revivity（NYSE:RVTY）BioLegend BUSINESS今天宣布推出一种新的同类产品TotalSeqTM PhenocyteTM单细胞蛋白质分析解决方案，该解决方案通过更容易地识别和表征稀有细胞亚型来支持客户，最终为免疫学和肿瘤学研究提供动力。

The solution is enabled by the proprietary combination of Scale Biosciences’ Quantum Barcoding technology platform and BioLegend’s TotalSeqTM antibody conjugates..

。。

While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples.

虽然像大规模细胞术和高参数流式细胞术这样的技术能够在单细胞水平上进行蛋白质分析，但这些方法需要复杂的面板优化和复杂的仪器，从而限制了它们在多个样品中的可访问性和可扩展性。

“By leveraging TotalSeq antibodies and a single-cell genomics-based workflow, this product supports the identification of low frequency events within a cell population. This allows for the study of many more markers than could be observed in a single experiment using other cell analysis technologies to study cell populations,” said Craig Monell, senior vice president, reagents, Revvity.

Revivity试剂高级副总裁克雷格·莫内尔（CraigMonell）说：“通过利用TotalSeq抗体和基于单细胞基因组学的工作流程，该产品支持识别细胞群中的低频事件。这使得可以研究比使用其他细胞分析技术研究细胞群的单个实验中观察到的更多的标记。”。

“Even with capital-intensive high parameter cytometry tools, we are not able to scale the same level of detection of rare cell types as we can with the TotalSeq Phenocyte solution.”.

“即使使用资本密集型高参数细胞计数工具，我们也无法像TotalSeq酚细胞解决方案那样扩展稀有细胞类型的检测水平。”。

“Scale Bio is focused on leveraging the power of our new Quantum Barcoding technology to enable researchers to dramatically scale up their research by being able to explore more cells, more samples, across more modalities, with simple workflows and an accessible price point. This is just the first of many Scale Bio offerings that will leverage our powerful single cell omics platform to enable more single cell omics insights,” said Giovanna Prout, president and CEO of Scale Bio.

Scale Bio总裁兼首席执行官乔瓦娜·普劳特（Giovanna Prout）表示：“Scale Bio专注于利用我们新的量子条形码技术的力量，通过简单的工作流程和可访问的价格点，能够探索更多的细胞，更多的样本，跨越更多的模式，使研究人员能够大幅扩大研究规模。这只是众多Scale Bio产品中的第一个，这些产品将利用我们强大的单细胞组学平台，实现更多的单细胞组学见解。”。

“The launch of the TotalSeq Phenocyte solution, made available through our collaboration with BioLegend, is the first time we’ve collaborated with another company to bring together disparate technologies into a single solution that supports our customers in upleveling their immunology and oncology research.”.

。

The new offering builds upon BioLegend’s well validated TotalSeq-ATM antibody panels and Scale Bio’s Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation..

新产品基于BioLegend经过充分验证的TotalSeq ATM抗体面板和Scale Bio的量子条形码技术工作流程。该组合产品可用于推动生物标志物的发现和异质群体中稀有细胞的鉴定，而无需复杂的面板设计，复杂的工作流程或专用仪器。。

“We are proud to collaborate with Scale Bio to bring our customers this novel, high parameter, protein-focused workflow to accelerate immunology and oncology research,” said Gene Lay, senior vice president, life sciences at Revvity. “This offering provides a cost-effective, high throughput solution that supports the study of rare cell subtypes, the acceleration of biomarker discovery, and the characterization of precious samples.”.

Revivity生命科学高级副总裁Gene Lay说：“我们很荣幸与Scale Bio合作，为我们的客户带来这种新颖的，高参数的，以蛋白质为中心的工作流程，以加速免疫学和肿瘤学研究。”。“该产品提供了一种具有成本效益的高通量解决方案，可支持稀有细胞亚型的研究，加速生物标志物的发现以及珍贵样品的表征。”。

The TotalSeq Phenocyte solution is now shipping.

TotalSeq Phenocyte解决方案现已上市。

For research use only. Not for use in diagnostic procedures.

仅供研究使用。不用于诊断程序。

About Scale Biosciences

关于规模生物科学

At Scale Bio, we are committed to accelerating scientific breakthroughs by providing innovative single cell omics solutions that redefine accessibility, flexibility, and scalability, empowering researchers to unlock the full potential of single cell omics. Leveraging our core massively parallelized single cell barcoding technology, we offer a range of advanced workflow solutions that maximize insights delivered with every experiment and sample type, allowing scientists to generate more data, analyze more samples, and explore more omics, cost efficiently and with unprecedented ease.

在Scale Bio，我们致力于通过提供创新的单细胞组学解决方案来加速科学突破，这些解决方案重新定义了可访问性，灵活性和可扩展性，使研究人员能够充分发挥单细胞组学的潜力。利用我们的核心大规模并行单细胞条形码技术，我们提供了一系列先进的工作流程解决方案，最大程度地提高了每个实验和样本类型的洞察力，使科学家能够生成更多数据，分析更多样本，探索更多组学，具有前所未有的成本效益和便利性。

Founded by scientists and technologists with experience across a range of multiomics disciplines, Scale Bio has attracted financing from leading life sciences tools investors including ARCH Venture Partners, BNG01 and Tao Capital. Scale Bio is headquartered in San Diego, Calif. Visit scale.bio to learn more..

Scale Bio由具有多学科经验的科学家和技术专家创立，吸引了包括ARCH Venture Partners、BNG01和Tao Capital在内的领先生命科学工具投资者的资金。Scale Bio总部位于加利福尼亚州圣地亚哥。访问Scale.Bio了解更多信息。。

About Revvity

关于Revivity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more..

在Revivity，“不可能”是灵感，“不可能”是行动的号召。Revivity提供健康科学解决方案、技术、专业知识和服务，提供从发现到开发、从诊断到治疗的完整工作流程。Revivity正在彻底改变医疗保健领域的可能性，专注于转化多组学技术、生物标志物识别、成像、预测、筛选、检测和诊断、信息学等领域。。

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Revivity在2023年的收入超过27亿美元，拥有11000多名员工，为制药和生物技术、诊断实验室、学术界和政府部门的客户提供服务。它是标准普尔500指数的一部分，在190多个国家拥有客户。

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

关注我们的新闻编辑室、LinkedIn、X、YouTube、Facebook和Instagram，随时了解最新信息。